{
    "Clinical Trial ID": "NCT01202591",
    "Intervention": [
        "INTERVENTION 1: ",
        "  AZD4547 80mg bd Cont + Ex 25mg",
        "  80 mg AZD4547 BD continuous + 25 mg exemestane",
        "INTERVENTION 2: ",
        "  AZD4547 40mg Cont + Ex 25mg",
        "  40 mg AZD4547 BD continuous + 25 mg exemestane"
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Post-menopausal women (either through bilateral oophorectomy or amenorrhoeic for 24 months)",
        "  Histological confirmation of Breast Cancer with documented ER+ receptor status",
        "  Safety run-in: Relapsing during/within 12 months of completion of a single regimen of adjuvant endocrine therapy with non-steroidal AI and/ tamoxifen or progression following 1st line endocrine therapy with non-steroidal AL",
        "  Rand phase IIa: Received at least 1 prior endocrine therapy in the metastatic setting or have relapsed during/ within 6 months of completion of adjuvant endocrine therapy (either non-steroidal AI or tamoxifen or a combination of both). Chemotherapy administered in the adjuvant setting is permitted.",
        "  Rand phase IIa: Mandatory provision of tumour sample to confirm FGFR1 polysomy or gene amplification. At least one measurable lesion that can be accurately assessed by CT/MRI/x-ray at baseline and follow up visits",
        "Exclusion Criteria:",
        "  Prior exposure to exemestane (safety run-in) / fulvestrant (randomized phase IIa), or any agent known to inhibit FGFRs.",
        "  More than 1 prior regimen of chemotherapy for breast cancer",
        "  ECG recordings that demonstrate significant abnormalities in cardiac rate, rhythm or conduction",
        "  History of hypersensitivity to active or inactive excipients of AZD4547 or exemestane (safety run-in ) or fulvestrant (Randomized phase), including castor oil, or drugs with a similar chemical structure or class to AZD4547 or exemestane or fulvestrant.",
        "  Randomized phase IIa: bleeding/blood clotting conditions that would prevent the administration of the fulvestrant injection into the buttocks"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Safety and Tolerability in Terms of Number of Patients With Adverse Events (Serious and Non-serious)",
        "  [Not Specified]",
        "  Time frame: 3 years, 10 months (Adverse events recorded from patient screening to discontinuation plus 28 days safety follow-up).",
        "Results 1: ",
        "  Arm/Group Title: AZD4547 80mg bd Cont + Ex 25mg",
        "  Arm/Group Description: 80 mg AZD4547 BD continuous + 25 mg exemestane",
        "  Overall Number of Participants Analyzed: 5",
        "  Measure Type: Number",
        "  Unit of Measure: Participants  5",
        "Results 2: ",
        "  Arm/Group Title: AZD4547 40mg Cont + Ex 25mg",
        "  Arm/Group Description: 40 mg AZD4547 BD continuous + 25 mg exemestane",
        "  Overall Number of Participants Analyzed: 5",
        "  Measure Type: Number",
        "  Unit of Measure: Participants  5"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 2/5 (40.00%)",
        "  ANAEMIA 0/5 (0.00%)",
        "  DIARRHOEA 0/5 (0.00%)",
        "  OESOPHAGEAL ACHALASIA 0/5 (0.00%)",
        "  STOMATITIS 0/5 (0.00%)",
        "  DEVICE DEPOSIT ISSUE 0/5 (0.00%)",
        "  INFLAMMATION 0/5 (0.00%)",
        "  GAIT DISTURBANCE 0/5 (0.00%)",
        "  LOWER RESPIRATORY TRACT INFECTION VIRAL 0/5 (0.00%)",
        "  NEUTROPENIC SEPSIS 1/5 (20.00%)",
        "  PLEURAL INFECTION 1/5 (20.00%)",
        "  PYELONEPHRITIS 0/5 (0.00%)",
        "Adverse Events 2:",
        "  Total: 2/5 (40.00%)",
        "  ANAEMIA 1/5 (20.00%)",
        "  DIARRHOEA 0/5 (0.00%)",
        "  OESOPHAGEAL ACHALASIA 0/5 (0.00%)",
        "  STOMATITIS 0/5 (0.00%)",
        "  DEVICE DEPOSIT ISSUE 0/5 (0.00%)",
        "  INFLAMMATION 0/5 (0.00%)",
        "  GAIT DISTURBANCE 0/5 (0.00%)",
        "  LOWER RESPIRATORY TRACT INFECTION VIRAL 0/5 (0.00%)",
        "  NEUTROPENIC SEPSIS 0/5 (0.00%)",
        "  PLEURAL INFECTION 0/5 (0.00%)",
        "  PYELONEPHRITIS 0/5 (0.00%)"
    ]
}